April 16, 2012
/PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported that more than 12,700 total tests, including in excess of 4,900 MaterniT21 PLUS laboratory-developed tests (LDT) offered by Sequenom Center for Molecular Medicine (Sequenom CMM), were accessioned during the first quarter of 2012. This equates to an annualized run rate in excess of 30,000 MaterniT21 PLUS LDTs, based on the volume processed during the last week of the quarter.
Due to the successful growth in adoption year-to-date, the Company is increasing its internal goal to 40,000 MaterniT21 PLUS LDTs billed in 2012, up from the original goal of 25,000 tests billed for the year.
"After the successful launch of the MaterniT21 PLUS LDT in 2011, Sequenom CMM has experienced growing demand for the test and weekly increases in samples received and billed during the early part of 2012," said
Harry F. Hixson
, Chairman and CEO of Sequenom, Inc. "We expect this trend to continue with Sequenom CMM's sustained commercial efforts throughout the year and have increased the internal goal to reflect our optimistic outlook."
Sequenom, Inc. will report its first quarter 2012 financial results after closing of the NASDAQ Global Market on
Thursday, May 3
, 2012. A conference call hosted by
Harry F. Hixson, Jr.
, Ph.D., Chairman and CEO, and other members of senior management will take place at
5:00 pm EDT
2:00 pm PDT
) and will be webcast live on the Sequenom website.
Conference Call Information
To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in
(both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom First Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through
, 2012. Interested parties can access the rebroadcast by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10012419.
The conference call webcast is accessible through the "Investors" section of the Sequenom website at
. An online replay will be available following the initial broadcast until
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in
San Diego, California
. Sequenom maintains a Web site at
to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM®) has two CAP accredited and CLIA-certified molecular diagnostics reference laboratories dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care. Testing services are available only upon request to physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit
for more information on laboratory testing services.
SEQUENOM®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom. All other trademarks and service marks are the property of their respective owners.